OHSS造成血液濃稠, MCV>45, WBC>15000, 卵巢>10cm,
http://humrep.oxfordjournals.org/content/22/5/1348.full
http://humrep.oxfordjournals.org/content/28/7/1929.full
Figure 2
Monitoring of (a) ovarian volume, (b) ascites, (c) hematocrit, (d) white blood cells, (e) estradiol and (f) progesterone in patients with severe early OHSS who were administered luteal GnRH antagonist. Oocyte retrieval was performed on Day 0. GnRH antagonist was administered for 3 days, from Day 5 until and including Day 7 post-oocyte retrieval, as indicated by grey boxes on x-axis. Embryo transfer was performed on Day 5. Asterisks depict statistical significance compared with Day 5 (*P < 0.05; **P < 0.01; ***P < 0.001).
Pregnancy outcomes for the high-risk patients who either did not develop severe OHSS (control) or developed severe OHSS and were administered GnRH antagonist in the luteal phase (OHSS + antag).
| OHSS + antag (n = 22) | Control (n = 172) | P | |
|---|---|---|---|
| Positive hCG test, n (%) | 16 (72.7) | 129 (75.0) | 0.798 |
| Clinical, n (%) | 11 (50.0) | 112 (65.1) | 0.239 |
| Ongoing, n (%) | 10 (45.5) | 84 (48.8) | 0.834 |
| Live birth, n (%) | 9 (40.9) | 75 (43.6) | 1.000 |
| Biochemical pregnancy | 5/16 (31.3) | 17/129 (13.2) | 0.070 |
| Clinical spontaneous abortion | 1/11 (9.1) | 27/112 (24.1) | 0.453 |
| Multiple pregnancy | 6/16 (37.5) | 57/129 (44.2) | 0.790 |
沒有留言:
張貼留言